Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Investigator: Jun Zhang, MD

Study Coordinator: Gabrielle Hayes

Status: Enrolling Number: NCT04911166

Phone: 734.419.948

Protocol Number: PRO00026826


This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chemotherapy.
More to Explore